Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...

In the early 2000s, the actress Priyanka Chopra underwent nose surgery to remove a nasal polyp, but unexpected complications ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Tezepelumab was first ...

A global drug trial to test the effectiveness of the asthma drug tezepelumab in treating nasal polyps has shown significant ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...